ifosfamide has been researched along with Rhabdomyosarcoma in 115 studies
Rhabdomyosarcoma: A malignant solid tumor arising from mesenchymal tissues which normally differentiate to form striated muscle. It can occur in a wide variety of sites. It is divided into four distinct types: pleomorphic, predominantly in male adults; alveolar (RHABDOMYOSARCOMA, ALVEOLAR), mainly in adolescents and young adults; embryonal (RHABDOMYOSARCOMA, EMBRYONAL), predominantly in infants and children; and botryoidal, also in young children. It is one of the most frequently occurring soft tissue sarcomas and the most common in children under 15. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p2186; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1647-9)
| Excerpt | Relevance | Reference |
|---|---|---|
| "In the prospective high-risk sarcoma (HIRISA) Phase II trial HIRISA1, pediatric patients with high-risk sarcomas received 3 cycles of intensive vincristine, ifosfamide, etoposide, cyclophosphamide, and doxorubicin (VACIE) before radiotherapy and/or surgery began at Week 9 with concurrent vincristine, cyclophosphamide, and doxorubicin (Week 9) and vincristine and ifosfamide (Week 12)." | 9.12 | Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk sarcomas: the St. Jude Children's Research Hospital experience. ( Billups, CA; Cain, AM; Furman, WL; Hale, GA; Merchant, TE; Navid, F; Pappo, AS; Rao, BN; Santana, VM; Spunt, SL, 2006) |
| "Children with recurrent/refractory sarcoma were treated with ifosfamide (1,800 mg/m2/day on day 0-4), carboplatin (400 mg/m2/day on day 0-1), etoposide (100 mg/m2/day on day 0-4) and either rhG-CSF (10 microg/kg/day vs." | 9.11 | Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience. ( Anderson, B; Angiolillo, A; Cairo, MS; Cheung, YK; Davenport, V; Krailo, M; Reaman, G; Van Winkle, P, 2005) |
| " ifosfamide and etoposide) and to improve overall survival of previously untreated patients with metastatic rhabdomyosarcoma." | 9.09 | Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group. ( Breitfeld, PP; Crist, WM; Donaldson, SS; Lobe, T; Lyden, E; Maurer, HM; Raney, RB; Ruymann, FB; Teot, LA; Wharam, M, 2001) |
| "The European Collaborative MMT4-91 trial was conducted as a prospective nonrandomized study to evaluate the potential benefit of high-dose melphalan as consolidation of first complete remission in children with stage IV rhabdomyosarcoma." | 9.09 | High-dose melphalan with autologous stem-cell rescue in metastatic rhabdomyosarcoma. ( Carli, M; Colombatti, R; Frascella, E; Koscielniak, E; Masiero, L; Oberlin, O; Pinkerton, CR; Stevens, M; Treuner, J, 1999) |
| "This Phase II study evaluated doxorubicin, dacarbazine, ifosfamide, and mesna (MAID) in adults with inoperable or metastatic Ewing's sarcoma, rhabdomyosarcoma, or osteosarcoma." | 9.08 | A Southwest Oncology Group and Cancer and Leukemia Group B phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in adults with advanced osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma. ( Antman, K; Baker, LH; Balcerzak, SP; Clamon, GH; Crowley, J; Kempf, RA; Weiss, RB, 1998) |
| "Ifosfamide appears to have significant clinical activity in untreated patients with unresectable rhabdomyosarcomas." | 9.07 | A phase II trial of ifosfamide in previously untreated children and adolescents with unresectable rhabdomyosarcoma. ( Bowman, LC; Crist, WM; Etcubanas, E; Fontanesi, J; Kun, LE; Pappo, AS; Rao, BN; Roberson, PK; Santana, VM; Shapiro, DN, 1993) |
| "The purpose of this review is to characterize the nephrotoxicity noted in newly diagnosed patients under 21 years of age after treatment with ifosfamide-containing chemotherapy regimens and local irradiation for localized gross residual rhabdomyosarcoma or undifferentiated sarcoma." | 9.07 | Renal toxicity of ifosfamide in pilot regimens of the intergroup rhabdomyosarcoma study for patients with gross residual tumor. ( Ensign, LG; Foreman, J; Khan, F; Maurer, H; Newton, W; Ortega, J; Ragab, A; Raney, B; Wharam, M; Wiener, E, 1994) |
| "The current study was performed to evaluate the toxicity profile of therapeutic doses of ifosfamide (IFX) given concurrently with full-dose external beam radiotherapy (EBRT) in patients with soft tissue and bone sarcomas." | 8.81 | Concurrent ifosfamide-based chemotherapy and irradiation. Analysis of treatment-related toxicity in 43 patients with sarcoma. ( Ballo, MT; Benjamin, RS; Burgess, MA; Cormier, JN; Feig, BW; Herzog, CE; Hunt, KK; Patel, SR; Pisters, PW; Raney, RB; Zagars, GK, 2001) |
| "The study reports the treatment feasibility, and secondly efficacy, of a novel chemotherapy regimen, which adds vinorelbine to the ifosfamide-vincristine-actinomycin-D combination (VIVA regimen), used in four patients with high-risk rhabdomyosarcoma." | 7.96 | VIVA (vinorelbine, ifosfamide, vincristine, actinomycin-D): A new regimen in the armamentarium of systemic therapy for high-risk rhabdomyosarcoma. ( Bergamaschi, L; Casanova, M; Chiaravalli, S; Ferrari, A; Pascale, S; Recupero, S; Zecca, M, 2020) |
| "Adjuvant ifosfamide appears to be safe and well tolerated in patients with completely resected uterine sarcoma." | 7.70 | Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma. ( Belinson, JL; Kennedy, AW; Kushner, DM; Markman, M; Rybicki, LA; Webster, KD, 2000) |
| "CWS/RMS-96 was an international multicenter trial with randomization between two therapy arms of the standard four-drug therapy (vincristine, ifosfamide, adriamycin, dactinomycin [VAIA]) versus an intensified six-drug regimen (carboplatin, epirubicin, vincristine, dactinomycin, ifosfamide, and etoposide [CEVAIE]) for high-risk rhabdomyosarcoma (RMS), extraskeletal Ewing sarcoma (EES), and undifferentiated sarcoma (UDS) in children, adolescents, and young adults aiming to improve their survival." | 5.51 | Long-term results from the multicentric European randomized phase 3 trial CWS/RMS-96 for localized high-risk soft tissue sarcoma in children, adolescents, and young adults. ( Alaggio, R; Bisogno, G; Casanova, M; Cecchetto, G; Ferrari, A; Kazanowska, B; Klingebiel, T; Koscielniak, E; Kosztyla, D; Ladenstein, R; Ljungman, G; Milano, GM; Niggli, F; Scarzello, G; Sparber-Sauer, M; Vokuhl, C; Zin, A, 2022) |
| "From July 1995 to June 2003, 457 previously untreated patients with incompletely resected embryonal rhabdomyosarcoma (RMS), undifferentiated sarcoma, and soft tissue primitive neuroectodermal tumor at all sites except paratesticular, vagina, and uterus, or with alveolar RMS were randomly assigned to receive either ifosfamide, vincristine, and dactinomycin (IVA) or a six-drug combination (IVA plus carboplatin, epirubicin, and etoposide) both delivered over 27 weeks." | 5.16 | Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatr ( Bergeron, C; Bouvet, N; Ellershaw, C; Jenney, ME; Kelsey, A; Martelli, H; Merks, JH; Oberlin, O; Rey, A; Sanchez de Toledo, J; Scopinaro, M; Spooner, D; Stevens, MC, 2012) |
| "In the prospective high-risk sarcoma (HIRISA) Phase II trial HIRISA1, pediatric patients with high-risk sarcomas received 3 cycles of intensive vincristine, ifosfamide, etoposide, cyclophosphamide, and doxorubicin (VACIE) before radiotherapy and/or surgery began at Week 9 with concurrent vincristine, cyclophosphamide, and doxorubicin (Week 9) and vincristine and ifosfamide (Week 12)." | 5.12 | Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk sarcomas: the St. Jude Children's Research Hospital experience. ( Billups, CA; Cain, AM; Furman, WL; Hale, GA; Merchant, TE; Navid, F; Pappo, AS; Rao, BN; Santana, VM; Spunt, SL, 2006) |
| "Children with recurrent/refractory sarcoma were treated with ifosfamide (1,800 mg/m2/day on day 0-4), carboplatin (400 mg/m2/day on day 0-1), etoposide (100 mg/m2/day on day 0-4) and either rhG-CSF (10 microg/kg/day vs." | 5.11 | Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience. ( Anderson, B; Angiolillo, A; Cairo, MS; Cheung, YK; Davenport, V; Krailo, M; Reaman, G; Van Winkle, P, 2005) |
| "From June 1997 to November 1999, 28 SRCT patients (median age, 26 years; 14 peripheral primitive neuroectodermal tumors [pPNETs], seven rhabdomyosarcomas [RMSs], and seven desmoplastic small round-cell tumors [DSRCTs]) received induction chemotherapy with ifosfamide, epirubicin, and vincristine followed by HD-CT." | 5.10 | High-dose chemotherapy in poor-prognosis adult small round-cell tumors: clinical and molecular results from a prospective study. ( Alloisio, M; Balzarotti, M; Bertuzzi, A; Castagna, L; Compasso, S; Nozza, A; Quagliuolo, V; Santoro, A; Siracusano, L; Soto Parra, H, 2002) |
| " ifosfamide and etoposide) and to improve overall survival of previously untreated patients with metastatic rhabdomyosarcoma." | 5.09 | Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group. ( Breitfeld, PP; Crist, WM; Donaldson, SS; Lobe, T; Lyden, E; Maurer, HM; Raney, RB; Ruymann, FB; Teot, LA; Wharam, M, 2001) |
| "The European Collaborative MMT4-91 trial was conducted as a prospective nonrandomized study to evaluate the potential benefit of high-dose melphalan as consolidation of first complete remission in children with stage IV rhabdomyosarcoma." | 5.09 | High-dose melphalan with autologous stem-cell rescue in metastatic rhabdomyosarcoma. ( Carli, M; Colombatti, R; Frascella, E; Koscielniak, E; Masiero, L; Oberlin, O; Pinkerton, CR; Stevens, M; Treuner, J, 1999) |
| "The Intergroup Rhabdomyosarcoma Study (IRS) initiated an escalating-dose cyclophosphamide (Cyc) pilot without hematopoietic growth factor (HGF) support in combination with vincristine (Vcr) and actinomycin-D (Amd), known as VAC, to establish a Cyc dose with myelotoxicity comparable to an ifosfamide (Ifos), Vcr, and Amd combination regimen (VAI)." | 5.08 | Cyclophosphamide dose escalation in combination with vincristine and actinomycin-D (VAC) in gross residual sarcoma. A pilot study without hematopoietic growth factor support evaluating toxicity and response. ( Gehan, E; Maurer, H; Newton, WA; Ruymann, FB; Vietti, T; Wharam, M; Wiener, E, 1995) |
| "This Phase II study evaluated doxorubicin, dacarbazine, ifosfamide, and mesna (MAID) in adults with inoperable or metastatic Ewing's sarcoma, rhabdomyosarcoma, or osteosarcoma." | 5.08 | A Southwest Oncology Group and Cancer and Leukemia Group B phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in adults with advanced osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma. ( Antman, K; Baker, LH; Balcerzak, SP; Clamon, GH; Crowley, J; Kempf, RA; Weiss, RB, 1998) |
| "The purpose of this review is to characterize the nephrotoxicity noted in newly diagnosed patients under 21 years of age after treatment with ifosfamide-containing chemotherapy regimens and local irradiation for localized gross residual rhabdomyosarcoma or undifferentiated sarcoma." | 5.07 | Renal toxicity of ifosfamide in pilot regimens of the intergroup rhabdomyosarcoma study for patients with gross residual tumor. ( Ensign, LG; Foreman, J; Khan, F; Maurer, H; Newton, W; Ortega, J; Ragab, A; Raney, B; Wharam, M; Wiener, E, 1994) |
| "We report the case of a 31-month-old girl, treated by the ifosfamide-vincristine-actinomycin chemotherapy protocol for vaginal rhabdomyosarcoma, who developed a unilateral left ptosis on day 36 of chemotherapy, i." | 4.89 | [Vincristine-induced unilateral ptosis: case report and review of the literature]. ( Angioi, K; Batta, B; Cloché, V; George, JL; Trechot, F, 2013) |
| "Phase II studies conducted in Europe and the USA on pediatric solid tumors have shown that ifosfamide, as a single agent, is an active drug against a variety of neoplasms - rhabdomyosarcoma (RMS), some non-RMS soft tissue sarcomas, Wilms' tumor, bone sarcomas and neuroblastoma." | 4.82 | Ifosfamide in pediatric solid tumors. ( Bisogno, G; Carli, M; Passone, E; Perilongo, G, 2003) |
| "The current study was performed to evaluate the toxicity profile of therapeutic doses of ifosfamide (IFX) given concurrently with full-dose external beam radiotherapy (EBRT) in patients with soft tissue and bone sarcomas." | 4.81 | Concurrent ifosfamide-based chemotherapy and irradiation. Analysis of treatment-related toxicity in 43 patients with sarcoma. ( Ballo, MT; Benjamin, RS; Burgess, MA; Cormier, JN; Feig, BW; Herzog, CE; Hunt, KK; Patel, SR; Pisters, PW; Raney, RB; Zagars, GK, 2001) |
| "We report on two children with rhabdomyosarcoma who received ifosfamide as part of their chemotherapy schedule." | 4.79 | Ifosfamide nephrotoxicity in children: histopathological features in two cases. ( Mann, JR; Milford, DV; Morland, BJ; Raafat, F; Stevens, MC, 1996) |
| " The most active single agents against osteosarcoma are doxorubicin (overall response rate, 21%), methotrexate (30% to 40%), cisplatin (25%), and ifosfamide (28%)." | 4.78 | Chemotherapy of advanced sarcomas of bone and soft tissue. ( Antman, KH, 1992) |
| "The study reports the treatment feasibility, and secondly efficacy, of a novel chemotherapy regimen, which adds vinorelbine to the ifosfamide-vincristine-actinomycin-D combination (VIVA regimen), used in four patients with high-risk rhabdomyosarcoma." | 3.96 | VIVA (vinorelbine, ifosfamide, vincristine, actinomycin-D): A new regimen in the armamentarium of systemic therapy for high-risk rhabdomyosarcoma. ( Bergamaschi, L; Casanova, M; Chiaravalli, S; Ferrari, A; Pascale, S; Recupero, S; Zecca, M, 2020) |
| "A 15-yearold boy with rhabdomyosarcoma was treated with a regimen of alternating cycles of vincristine, doxorubicin, and cyclophosphamide (VDC) chemotherapy and ifosfamide and etoposide (IE) chemotherapy." | 3.83 | Ifosfamide and etoposide chemotherapy may interact with warfarin, enhancing the warfarin induced anticoagulant response. ( Ishizawa, K; Kagami, S; Okada, N; Watanabe, H, 2016) |
| "AEs observed during 1 of 3 randomized chemotherapy regimens (vincristine, dactinomycin, and cyclophosphamide [VAC]; vincristine, dactinomycin, and ifosfamide [VAI]; or vincristine, ifosfamide, and etoposide [VIE]) in the Fourth Intergroup Rhabdomyosarcoma Study were recorded." | 3.78 | Patterns of chemotherapy-induced toxicities in younger children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee. ( Anderson, JR; Dasgupta, R; Gupta, AA; Hawkins, DS; Indelicato, DJ; Pappo, AS; Spunt, SL, 2012) |
| " Although epilepsy-like symptoms occurred at the first course of VIP therapy, these symptoms immediately improved by diazepam administration." | 3.72 | [A case of advanced rhabdomyosarcoma of the spermatic cord who occurred epilepsy-like symptoms, but was completely responded to chemotherapy]. ( Kobayashi, M; Suzuki, K; Tokue, A, 2004) |
| "Adjuvant ifosfamide appears to be safe and well tolerated in patients with completely resected uterine sarcoma." | 3.70 | Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma. ( Belinson, JL; Kennedy, AW; Kushner, DM; Markman, M; Rybicki, LA; Webster, KD, 2000) |
| "Neuroblastomas, nephroblastomas, malignant mesenchymal tumors, including rhabdomyosarcomas, Ewing's sarcomas, osteosarcomas, brain tumors, and non-Hodgkin's lymphomas respond to ifosfamide monotherapy." | 3.69 | Ifosfamide in the treatment of pediatric malignancies. ( Behrendt, H; de Kraker, J; Michiels, E; van den Berg, H; Voûte, PA, 1996) |
| "Disease progression was discovered when the patient got adjuvant epirubicin, ifosfamide, and bevacizumab for 2 cycles." | 3.01 | Perianal rhabdomyosarcoma in an adult: A case report and review of the literature. ( Kong, D; Liu, Y; Wang, X; Yang, N, 2023) |
| " A novel five-drug combination of etoposide, vincristine, dactinomycin, ifosfamide, and doxorubicin (EVAIA) was evaluated for high-risk patients, but cumulative chemotherapy dosage and treatment duration were reduced for the remaining individuals as compared with that of the previous trial CWS-86." | 2.74 | Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults. ( Bielack, SS; Brecht, I; Dantonello, TM; Dickerhoff, R; Gadner, H; Greiner, J; Greulich, M; Harms, D; Herbst, M; Int-Veen, C; Juergens, H; Kirsch, S; Klingebiel, T; Koscielniak, E; Leuschner, I; Marky, I; Scheel-Walter, HG; Schmelzle, R; Schmidt, BF; Treuner, J, 2009) |
| "Osteosarcoma is a clinically heterogeneous disease which continues to resist biologic diagnosis, classification, or staging." | 2.39 | Problems and controversies in the management of childhood sarcomas. ( Womer, RB, 1996) |
| "The incidence of secondary onset of second neoplasms in children with malignant solid tumors is not high, considering that this is correlated to the use of alkylating agents, topoisomerase II inhibitors, platinum-based chemotherapy drugs and radiotherapy, and associated with the chromosomal abnormalities of children." | 1.72 | A report on second neo-plasms in seven children with solid tumors. ( Hu, H; Huang, D; Li, F; Li, J; Li, R; Liu, Z; Zhang, W, 2022) |
| "Ifosfamid-related encephalopathy (IRE) is a rare but severe adverse event, without clearly identified risk factors." | 1.46 | [Incidence and risk factors for ifosfamide-related encephalopathy in sarcoma patients]. ( Defachelles, AS; Deplanque, D; Lervat, C; Marliot, G; Penel, N; Peugniez, C; Ryckewaert, T; Sakji, I; Stern, N, 2017) |
| "Rhabdomyosarcoma is an aggressive malignant tumor of childhood, originating from immature cells that are destinated to form striated skeletal muscle." | 1.43 | Primary diffuse pleural rhabdomyosarcoma in an adult patient. ( Bugdayci, M; Emri, S; Gedikoglu, G; Ibrahimov, F; Koksal, D, 2016) |
| "Nodal relapse is also associated with a high mortality rate." | 1.40 | Diagnosis and treatment of lymph node metastases in pediatric rhabdomyosarcoma in the Netherlands: a retrospective analysis. ( Heij, HA; Merks, JH; Spronk, P; Terwisscha van Scheltinga, CE; van Baren, R; van Noesel, MM; van Rosmalen, J; Wijnen, MH; Wijnen, RM, 2014) |
| "The spindle cell rhabdomyosarcoma is a rare variant of the embryonal rhabdomyosarcoma, mostly occurring in childhood." | 1.39 | Spindle cell rhabdomyosarcoma of the prostate. ( Ellinger, J; Fechner, G; Goltz, D; Latz, S; Leuschner, I; Marx, C; Müller, SC, 2013) |
| "All patients revealed intracranial metastases manifesting as rapidly progressing neurological symptoms caused by mass effect in the posterior fossa." | 1.37 | Infratentorial brain metastases of pediatric non-epithelial malignant tumors: three case reports. ( Kumabe, T; Niizuma, H; Osawa, S; Saito, R; Sonoda, Y; Tominaga, T; Watanabe, M, 2011) |
| "Rhabdomyosarcoma is an exceedingly rare tumor in adults, and standard chemotherapy used for children is much less effective in adults." | 1.36 | Treatment of adult rhabdomyosarcoma. ( Crawford, EA; Hartner, L; King, JJ; Lackman, RD; Ogilvie, CM; Slotcavage, RL; Staddon, AP, 2010) |
| "Orbital or sinus rhabdomyosarcoma is seen almost exclusively in the pediatric population, but may very rarely occur in adults." | 1.35 | Stage IV primitive-appearing sinus and orbital rhabdomyosarcoma presenting in a 68-year-old female previously treated for breast cancer. ( Chesnutt, DA; Cummings, TJ; Heimann, A; Morris, CL; Mukundan, S, 2008) |
| "Rhabdomyosarcoma is the most common childhood primary orbital malignancy, but the occurrence of this tumour in the conjunctiva is rare." | 1.33 | A case of primary botryoid conjunctival rhabdomyosarcoma. ( Lasorella, G; Loffredo, A; Pichierri, P; Polito, E, 2006) |
| "Although rapid disease progression had resolved transiently, after the start of high-dose chemotherapy, re-progression was apparently observed from day 14." | 1.32 | Regression of refractory rhabdomyosarcoma after allogeneic stem-cell transplantation. ( Hosoi, H; Iehara, T; Misawa, A; Sawada, T; Sugimoto, T; Tsuchiya, K, 2003) |
| "Patients had Ewing's sarcoma/primitive neuroectodermal tumour (PNET), rhabdomyosarcoma, non-rhabdo soft tissue sarcomas or other advanced soft tissue tumours." | 1.31 | Granulocyte colony stimulating factor permits dose intensification by interval compression in the treatment of Ewing's sarcomas and soft tissue sarcomas in children. ( Daller, RT; Fenton, JG; Miser, JS; Womer, RB, 2000) |
| "A case of uterine rhabdomyosarcoma is presented." | 1.31 | Rhabdomyosarcoma of the corpus of the uterus: a case report. ( Moerman, PH; Scheidt, P; Vergote, I, 2000) |
| "Prospective, multicenter study in 44 soft tissue sarcoma (STS) patients with first relapse." | 1.30 | Treatment of children with relapsed soft tissue sarcoma: report of the German CESS/CWS REZ 91 trial. ( Hess, CF; Jürgens, H; Klingebiel, T; Koscielniak, E; Pertl, U; Pötter, R; Rossi, R; Schött, C; Spaar, HJ; Treuner, J; van Heek-Romanowski, R; Willnow, U, 1998) |
| "Ifosfamide is an alkylating agent which has been incorporated into frontline therapy for a number of malignant paediatric tumours." | 1.29 | Ifosfamide nephrotoxicity in paediatric cancer patients. ( Ashraf, MS; Brady, J; Breatnach, F; Deasy, PF; O'Meara, A, 1994) |
| "We describe 2 cases of proximal tubular defects induced by the administration of ifosfamide at a dosage of 6 g/m2/course over 2 days in children with a diagnosis of malignant mesenchymal tumors." | 1.29 | Ifosfamide-induced renal tubular defect. ( López Pérez, J; Melero, C; Muley, R; Torres Valdivieso, MJ; Vara, J; Vivanco, JL, 1994) |
| " Similar results were found in toxicity and pharmacokinetic studies conducted in non-tumor-bearing female CBA/CaJ mice." | 1.28 | Efficacy, toxicity, pharmacokinetics, and in vitro metabolism of the enantiomers of ifosfamide in mice. ( Houghton, PJ; Masurel, D; Wainer, IW; Young, CL, 1990) |
| "12 patients with extensive metastases of malignant testicular tumors and 5 other patients with other rapidly growing metastasizing tumors were treated." | 1.25 | [Cytostatic therapy of tumors under conditions of partial synchronisation with particular reference to malignant tumors of the testicle (author's transl)]. ( Jonas, U; Körner, F; Lund, S, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (8.70) | 18.7374 |
| 1990's | 33 (28.70) | 18.2507 |
| 2000's | 35 (30.43) | 29.6817 |
| 2010's | 26 (22.61) | 24.3611 |
| 2020's | 11 (9.57) | 2.80 |
| Authors | Studies |
|---|---|
| Sparber-Sauer, M | 2 |
| Ferrari, A | 6 |
| Kosztyla, D | 1 |
| Ladenstein, R | 1 |
| Cecchetto, G | 1 |
| Kazanowska, B | 1 |
| Scarzello, G | 1 |
| Ljungman, G | 1 |
| Milano, GM | 1 |
| Niggli, F | 1 |
| Alaggio, R | 1 |
| Vokuhl, C | 2 |
| Casanova, M | 4 |
| Klingebiel, T | 3 |
| Zin, A | 1 |
| Koscielniak, E | 6 |
| Bisogno, G | 6 |
| Schoot, RA | 1 |
| Chisholm, JC | 1 |
| Minard-Colin, V | 1 |
| Geoerger, B | 1 |
| Cameron, AL | 1 |
| Coppadoro, B | 2 |
| Zanetti, I | 1 |
| Orbach, D | 5 |
| Kelsey, A | 2 |
| Rogers, T | 2 |
| Guizani, C | 1 |
| Elze, M | 1 |
| Ben-Arush, M | 1 |
| McHugh, K | 1 |
| van Rijn, RR | 1 |
| Ferman, S | 1 |
| Gallego, S | 1 |
| Jenney, M | 1 |
| Merks, JHM | 2 |
| Hu, H | 1 |
| Zhang, W | 1 |
| Li, J | 1 |
| Li, F | 1 |
| Li, R | 1 |
| Liu, Z | 1 |
| Huang, D | 1 |
| Fuchs, J | 1 |
| Dasgupta, R | 2 |
| Haduong, JH | 1 |
| Walterhouse, DO | 1 |
| Xue, W | 1 |
| Hawkins, DS | 5 |
| Seitz, G | 1 |
| Venkatramani, R | 1 |
| Qu, S | 1 |
| Li, W | 1 |
| Yao, Y | 1 |
| Huang, H | 1 |
| Yang, N | 1 |
| Kong, D | 1 |
| Wang, X | 1 |
| Liu, Y | 1 |
| Ito, M | 1 |
| Yagasaki, H | 1 |
| Oba, D | 1 |
| Hirai, M | 1 |
| Kaneda, H | 1 |
| Morioka, I | 1 |
| Chiaravalli, S | 2 |
| Zecca, M | 1 |
| Recupero, S | 1 |
| Pascale, S | 1 |
| Bergamaschi, L | 2 |
| Gordon, K | 1 |
| Ahmad, N | 1 |
| Benkhaled, S | 1 |
| Mané, M | 1 |
| Jungels, C | 1 |
| Shumelinsky, F | 1 |
| Aubain, NS | 1 |
| Van Gestel, D | 1 |
| Elsebaie, MAT | 1 |
| Amgad, M | 1 |
| Elkashash, A | 1 |
| Elgebaly, AS | 1 |
| Ashal, GGEL | 1 |
| Shash, E | 1 |
| Elsayed, Z | 1 |
| Arndt, CAS | 1 |
| Assi, T | 1 |
| El Rassy, E | 1 |
| Abi-Tayeh, G | 1 |
| Sader-Ghorra, C | 1 |
| Abadjian, G | 1 |
| Eid, R | 1 |
| Moussa, T | 1 |
| Farhat, F | 1 |
| Kattan, J | 1 |
| Bertulli, R | 1 |
| Provenzano, S | 1 |
| Gasparini, P | 1 |
| Collini, P | 1 |
| Sangalli, C | 1 |
| Gandola, L | 1 |
| Diletto, B | 1 |
| Morosi, C | 1 |
| Fiore, M | 1 |
| Massimino, M | 2 |
| Batta, B | 1 |
| Trechot, F | 1 |
| Cloché, V | 1 |
| George, JL | 1 |
| Angioi, K | 1 |
| Terwisscha van Scheltinga, CE | 1 |
| Spronk, P | 1 |
| van Rosmalen, J | 1 |
| Wijnen, MH | 1 |
| Heij, HA | 1 |
| van Baren, R | 1 |
| Merks, JH | 2 |
| van Noesel, MM | 1 |
| Wijnen, RM | 1 |
| Boutroux, H | 1 |
| Cellier, C | 1 |
| Mosseri, V | 2 |
| Helfre, S | 1 |
| Levy, C | 1 |
| Desjardins, L | 1 |
| Plancher, C | 1 |
| Freneaux, P | 1 |
| Michon, J | 1 |
| Winter, S | 1 |
| Fasola, S | 1 |
| Brisse, H | 1 |
| Koksal, D | 1 |
| Ibrahimov, F | 1 |
| Bugdayci, M | 1 |
| Gedikoglu, G | 1 |
| Emri, S | 1 |
| Weigel, BJ | 1 |
| Lyden, E | 3 |
| Anderson, JR | 5 |
| Meyer, WH | 4 |
| Parham, DM | 1 |
| Rodeberg, DA | 1 |
| Michalski, JM | 1 |
| Arndt, CA | 3 |
| Noujaim, J | 1 |
| Thway, K | 1 |
| Jones, RL | 1 |
| Miah, A | 1 |
| Khabra, K | 1 |
| Langer, R | 1 |
| Kasper, B | 1 |
| Judson, I | 1 |
| Benson, C | 1 |
| Kollàr, A | 1 |
| Okada, N | 1 |
| Watanabe, H | 1 |
| Kagami, S | 1 |
| Ishizawa, K | 1 |
| Sasada, S | 1 |
| Kodaira, M | 1 |
| Shimoi, T | 1 |
| Shimomura, A | 1 |
| Yunokawa, M | 1 |
| Yonemori, K | 1 |
| Shimizu, C | 1 |
| Fujiwara, Y | 1 |
| Tamura, K | 1 |
| Stern, N | 1 |
| Sakji, I | 1 |
| Defachelles, AS | 2 |
| Lervat, C | 1 |
| Ryckewaert, T | 1 |
| Marliot, G | 1 |
| Peugniez, C | 1 |
| Deplanque, D | 1 |
| Penel, N | 2 |
| Kim, YD | 1 |
| Kim, KJ | 1 |
| Lee, YH | 1 |
| Fayette, J | 1 |
| Chevreau, C | 1 |
| Blay, JY | 1 |
| Cupissol, D | 1 |
| Thyss, A | 1 |
| Guillemet, C | 1 |
| Rios, M | 1 |
| Rolland, F | 1 |
| Fargeot, P | 1 |
| Bay, JO | 1 |
| Mathoulin-Pelissier, S | 1 |
| Coindre, JM | 1 |
| Bui-Nguyen, B | 1 |
| Dantonello, TM | 1 |
| Int-Veen, C | 1 |
| Harms, D | 1 |
| Leuschner, I | 2 |
| Schmidt, BF | 1 |
| Herbst, M | 1 |
| Juergens, H | 1 |
| Scheel-Walter, HG | 1 |
| Bielack, SS | 1 |
| Dickerhoff, R | 1 |
| Kirsch, S | 1 |
| Brecht, I | 1 |
| Schmelzle, R | 2 |
| Greulich, M | 1 |
| Gadner, H | 1 |
| Greiner, J | 1 |
| Marky, I | 1 |
| Treuner, J | 5 |
| Lashkari, A | 1 |
| Chow, WA | 1 |
| Valdes, F | 1 |
| Leong, L | 1 |
| Phan, V | 1 |
| Twardowski, P | 1 |
| Kapoor, N | 1 |
| Molina, A | 1 |
| Al-Kadhimi, Z | 1 |
| Frankel, P | 1 |
| Somlo, G | 1 |
| Ogilvie, CM | 1 |
| Crawford, EA | 1 |
| Slotcavage, RL | 1 |
| King, JJ | 1 |
| Lackman, RD | 1 |
| Hartner, L | 1 |
| Staddon, AP | 1 |
| Oberlin, O | 8 |
| Fawaz, O | 1 |
| Rey, A | 6 |
| Niaudet, P | 1 |
| Ridola, V | 1 |
| Bergeron, C | 2 |
| Gentet, JC | 2 |
| Schmitt, C | 1 |
| Rubie, H | 1 |
| Munzer, M | 1 |
| Plantaz, D | 2 |
| Deville, A | 1 |
| Minard, V | 1 |
| Corradini, N | 1 |
| Leverger, G | 1 |
| de Vathaire, F | 1 |
| Bernard, PA | 1 |
| McCabe, T | 1 |
| Bayliff, S | 1 |
| Hayes, D | 1 |
| Cai, JY | 1 |
| Tang, JY | 1 |
| Pan, C | 1 |
| Xu, M | 1 |
| Xue, HL | 1 |
| Zhou, M | 1 |
| Dong, L | 1 |
| Ye, QD | 1 |
| Jiang, H | 1 |
| Shen, SH | 1 |
| Chen, J | 1 |
| Osawa, S | 1 |
| Kumabe, T | 1 |
| Saito, R | 1 |
| Sonoda, Y | 1 |
| Niizuma, H | 1 |
| Watanabe, M | 1 |
| Tominaga, T | 1 |
| Deroussent, A | 1 |
| Rodriguez, S | 1 |
| Martelli, S | 1 |
| Seck, A | 1 |
| Dubus-Daudigeos, E | 1 |
| Desmaële, D | 1 |
| Vassal, G | 1 |
| Paci, A | 1 |
| Chen, N | 1 |
| Hanly, L | 1 |
| Rieder, M | 1 |
| Yeger, H | 1 |
| Koren, G | 1 |
| Zhang, Y | 1 |
| Zhang, WL | 1 |
| Huang, DS | 1 |
| Yang, YP | 1 |
| Liu, XC | 1 |
| Wu, YP | 1 |
| Gupta, AA | 1 |
| Pappo, AS | 6 |
| Spunt, SL | 2 |
| Indelicato, DJ | 1 |
| Sanchez de Toledo, J | 3 |
| Martelli, H | 4 |
| Jenney, ME | 1 |
| Scopinaro, M | 1 |
| Bouvet, N | 3 |
| Ellershaw, C | 2 |
| Spooner, D | 2 |
| Stevens, MC | 6 |
| Kim, NK | 1 |
| Kim, HS | 1 |
| Suh, CO | 1 |
| Kim, HO | 1 |
| Lyu, CJ | 1 |
| Cranmer, LD | 1 |
| Chen, CC | 1 |
| Morgan, S | 1 |
| Martino, G | 1 |
| Ray, J | 1 |
| Latz, S | 1 |
| Ellinger, J | 1 |
| Goltz, D | 1 |
| Marx, C | 1 |
| Müller, SC | 1 |
| Fechner, G | 1 |
| Rozan, O | 1 |
| Janot, F | 1 |
| Schwaab, G | 1 |
| Quintana, E | 5 |
| Tran Ba Huy, P | 1 |
| Georges, B | 1 |
| Luboinski, B | 1 |
| Misawa, A | 1 |
| Hosoi, H | 1 |
| Tsuchiya, K | 1 |
| Iehara, T | 1 |
| Sawada, T | 1 |
| Sugimoto, T | 1 |
| Stewart, RJ | 1 |
| Spicer, RD | 2 |
| Godzinski, J | 1 |
| Carli, M | 2 |
| Passone, E | 1 |
| Perilongo, G | 1 |
| Kita, M | 1 |
| Sasaki, Y | 1 |
| Okuyama, M | 1 |
| Saga, Y | 1 |
| Hashimoto, H | 1 |
| Kaneko, S | 1 |
| Yachiku, S | 1 |
| Tokumitsu, M | 1 |
| Inada, F | 1 |
| Ishida, H | 1 |
| Komdeur, R | 1 |
| Meijer, C | 1 |
| Van Zweeden, M | 1 |
| De Jong, S | 1 |
| Wesseling, J | 1 |
| Hoekstra, HJ | 1 |
| van der Graaf, WT | 1 |
| Suzuki, K | 1 |
| Kobayashi, M | 1 |
| Tokue, A | 1 |
| Goto, T | 1 |
| Kosaku, H | 1 |
| Kobayashi, H | 1 |
| Hozumi, T | 1 |
| Kondo, T | 1 |
| Van Winkle, P | 1 |
| Angiolillo, A | 1 |
| Krailo, M | 1 |
| Cheung, YK | 1 |
| Anderson, B | 1 |
| Davenport, V | 1 |
| Reaman, G | 1 |
| Cairo, MS | 1 |
| Flamant, F | 5 |
| Habrand, JL | 2 |
| Marsden, HB | 1 |
| Terrier-Lacombe, MJ | 3 |
| van Unnik, A | 2 |
| Polito, E | 1 |
| Pichierri, P | 1 |
| Loffredo, A | 1 |
| Lasorella, G | 1 |
| Navid, F | 1 |
| Santana, VM | 2 |
| Billups, CA | 1 |
| Merchant, TE | 1 |
| Furman, WL | 1 |
| Cain, AM | 1 |
| Rao, BN | 2 |
| Hale, GA | 1 |
| Derikx, JP | 1 |
| van Waardenburg, DA | 1 |
| Granzen, B | 1 |
| van Bijnen, AA | 1 |
| Heineman, E | 1 |
| Buurman, WA | 1 |
| Lager, JJ | 1 |
| Lyden, ER | 1 |
| Breitfeld, PP | 2 |
| Meza, JL | 1 |
| Anderson, J | 1 |
| Li, EX | 1 |
| Zhang, YT | 1 |
| Shang, JT | 1 |
| Xu, Z | 1 |
| Geng, Y | 1 |
| Li, SM | 1 |
| Shi, F | 1 |
| Wu, YY | 1 |
| Sencer, SF | 2 |
| Neglia, JP | 2 |
| Morris, CL | 1 |
| Mukundan, S | 1 |
| Heimann, A | 1 |
| Cummings, TJ | 1 |
| Chesnutt, DA | 1 |
| Utracka-Hutka, B | 1 |
| Czownicki, Z | 1 |
| Torres Valdivieso, MJ | 1 |
| López Pérez, J | 1 |
| Melero, C | 1 |
| Vivanco, JL | 1 |
| Muley, R | 1 |
| Vara, J | 1 |
| Rousseau, P | 1 |
| Voute, PA | 5 |
| Ruymann, FB | 2 |
| Vietti, T | 1 |
| Gehan, E | 1 |
| Wiener, E | 2 |
| Wharam, M | 4 |
| Newton, WA | 1 |
| Maurer, H | 3 |
| Raney, B | 1 |
| Ensign, LG | 1 |
| Foreman, J | 1 |
| Khan, F | 1 |
| Newton, W | 1 |
| Ortega, J | 1 |
| Ragab, A | 1 |
| Rao, SP | 1 |
| Miller, ST | 1 |
| Cohen, BJ | 1 |
| Ashraf, MS | 2 |
| Brady, J | 1 |
| Breatnach, F | 1 |
| Deasy, PF | 1 |
| O'Meara, A | 1 |
| Hartley, JM | 1 |
| Hansen, L | 1 |
| Harland, SJ | 1 |
| Nicholson, PW | 1 |
| Pasini, F | 1 |
| Souhami, RL | 1 |
| Otsuka, T | 1 |
| Matsui, N | 1 |
| Ohta, H | 1 |
| Hattori, M | 1 |
| Nakamura, T | 1 |
| Etcubanas, E | 1 |
| Kun, LE | 1 |
| Fontanesi, J | 1 |
| Roberson, PK | 1 |
| Bowman, LC | 1 |
| Crist, WM | 3 |
| Shapiro, DN | 1 |
| Palmer, MA | 1 |
| Viswanath, S | 1 |
| Desmond, AD | 1 |
| Morland, BJ | 1 |
| Mann, JR | 1 |
| Milford, DV | 1 |
| Raafat, F | 1 |
| van den Berg, H | 1 |
| Behrendt, H | 1 |
| Michiels, E | 1 |
| de Kraker, J | 1 |
| Womer, RB | 3 |
| Skinner, R | 3 |
| English, MW | 1 |
| Craft, AW | 2 |
| Pearson, AD | 3 |
| Lackner, H | 1 |
| Urban, C | 1 |
| Cefalo, G | 1 |
| Tesoro-Tess, JD | 1 |
| Gianni, MC | 1 |
| Fossati-Bellani, F | 1 |
| Lombardi, F | 1 |
| Antman, K | 1 |
| Crowley, J | 1 |
| Balcerzak, SP | 1 |
| Kempf, RA | 1 |
| Weiss, RB | 1 |
| Clamon, GH | 1 |
| Baker, LH | 1 |
| Pertl, U | 1 |
| Hess, CF | 1 |
| Jürgens, H | 1 |
| Pötter, R | 1 |
| van Heek-Romanowski, R | 1 |
| Rossi, R | 1 |
| Schött, C | 1 |
| Spaar, HJ | 1 |
| Willnow, U | 1 |
| Pollono, DG | 1 |
| Tomarchio, S | 1 |
| Berghoff, R | 1 |
| Drut, R | 1 |
| Urrutia, A | 1 |
| Cédola, J | 1 |
| Friedlaender, MM | 1 |
| Haviv, YS | 1 |
| Rosenmann, E | 1 |
| Peylan-Ramu, N | 1 |
| Yule, SM | 1 |
| Price, L | 2 |
| Boddy, AV | 1 |
| Rodary, C | 2 |
| Praquin, MT | 1 |
| Sommelet, D | 1 |
| Theobald, S | 1 |
| Brunat-Mentigny, M | 2 |
| Otten, J | 2 |
| Barrett, A | 1 |
| Nascimento, AG | 1 |
| Schroeder, G | 1 |
| Schomberg, PJ | 1 |
| Silberman, TL | 1 |
| Moertel, CL | 1 |
| Tillisch, JK | 1 |
| Miser, JS | 2 |
| Colombatti, R | 1 |
| Stevens, M | 1 |
| Masiero, L | 1 |
| Frascella, E | 1 |
| Pinkerton, CR | 1 |
| Daller, RT | 1 |
| Fenton, JG | 1 |
| Cotterill, SJ | 1 |
| Kushner, DM | 1 |
| Webster, KD | 1 |
| Belinson, JL | 1 |
| Rybicki, LA | 1 |
| Kennedy, AW | 1 |
| Markman, M | 1 |
| Scheidt, P | 1 |
| Moerman, PH | 1 |
| Vergote, I | 1 |
| De Raeve, H | 1 |
| Jeuris, W | 1 |
| Wyndaele, JJ | 1 |
| Van Marck, E | 1 |
| Cormier, JN | 1 |
| Patel, SR | 1 |
| Herzog, CE | 1 |
| Ballo, MT | 1 |
| Burgess, MA | 1 |
| Feig, BW | 1 |
| Hunt, KK | 1 |
| Raney, RB | 3 |
| Zagars, GK | 1 |
| Benjamin, RS | 1 |
| Pisters, PW | 1 |
| Sandler, E | 1 |
| Ruymann, F | 1 |
| Parham, D | 1 |
| Link, M | 1 |
| Crist, W | 1 |
| De Neve, W | 1 |
| Claus, F | 1 |
| Duthoy, W | 1 |
| De Meerleer, G | 1 |
| De Wagter, C | 1 |
| Barr, FG | 1 |
| Donaldson, SS | 2 |
| Qualman, SJ | 1 |
| Wiener, ES | 1 |
| Maurer, HM | 2 |
| Teot, LA | 1 |
| Lobe, T | 1 |
| Bertuzzi, A | 1 |
| Castagna, L | 1 |
| Nozza, A | 1 |
| Quagliuolo, V | 1 |
| Siracusano, L | 1 |
| Balzarotti, M | 1 |
| Compasso, S | 1 |
| Alloisio, M | 1 |
| Soto Parra, H | 1 |
| Santoro, A | 1 |
| Körner, F | 1 |
| Lund, S | 1 |
| Jonas, U | 1 |
| Bachelot, C | 1 |
| Dyon, JF | 1 |
| Pasquier, D | 1 |
| Baudain, P | 1 |
| Durand, C | 1 |
| Bost, M | 1 |
| Coene, IJ | 1 |
| Schouwenburg, PF | 1 |
| Marion, J | 1 |
| Burgers, V | 1 |
| Hilgers, FJ | 1 |
| Rea, F | 1 |
| Loy, M | 1 |
| Bonavina, L | 1 |
| Vigo, M | 1 |
| Salmaso, R | 1 |
| Calabrò, F | 1 |
| Antman, KH | 1 |
| Van Gool, S | 1 |
| Brock, P | 1 |
| Wijndaele, G | 1 |
| Van de Casseye, W | 1 |
| Kruger, M | 1 |
| Proesmans, W | 1 |
| Casteels-Van Daele, M | 1 |
| Iwasaku-Fujimoto, M | 1 |
| Fujiwara, F | 1 |
| Todo, S | 1 |
| Morioka, Y | 1 |
| Imashuku, S | 1 |
| Masurel, D | 1 |
| Houghton, PJ | 1 |
| Young, CL | 1 |
| Wainer, IW | 1 |
| Klesper, B | 1 |
| Hartmann, N | 1 |
| Kim, MJ | 1 |
| Cunningham, K | 1 |
| Verdeguer, A | 1 |
| Castel, V | 1 |
| Esquembre, C | 1 |
| Ferris, J | 1 |
| Fernandez, JM | 1 |
| Ruiz, JG | 1 |
| Newbury-Ecob, RA | 1 |
| Noble, VW | 1 |
| Barbor, PR | 1 |
| Dutou, L | 1 |
| Olive, D | 1 |
| Keim, M | 2 |
| Suder, J | 1 |
| Kaatsch, P | 1 |
| Niethammer, D | 1 |
| Fernandez, H | 1 |
| Diallo, A | 1 |
| Baume, D | 1 |
| Papiernik, E | 1 |
| Salloum, E | 1 |
| Ghosn, M | 1 |
| Taleb, N | 1 |
| Akatchereian, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Analyzing Engagement Trends in Rhabdomyosarcoma Clinical Trials: A Study of Participation Patterns Among Those Affected by the Disorder[NCT06029465] | 500 participants (Anticipated) | Observational | 2024-10-31 | Not yet recruiting | |||
| An Open-label, Multi-center, Randomized Study of the Safety and Effect on Event-free Survival of Bevacizumab in Combination With Standard Chemotherapy in Childhood and Adolescent Patients With Metastatic Rhabdomyosarcoma and Non-rhabdomyosarcoma Soft Tiss[NCT00643565] | Phase 2 | 154 participants (Actual) | Interventional | 2008-07-29 | Completed | ||
| A Protocol For Nonmetastatic Rhabdomyosarcoma [RMS-2005][NCT00379457] | Phase 3 | 600 participants (Anticipated) | Interventional | 2006-06-30 | Recruiting | ||
| A Randomised Phase-III Trial of the Cooperative Weichteilsarkom Study Group (CWS) for Localised High-risk Rhabdomyosarcoma and Localised Rhabdomyosarcoma-like Soft Tissue Sarcoma in Children, Adolescents, and Young Adults[NCT00876031] | Phase 3 | 195 participants (Actual) | Interventional | 2009-07-01 | Completed | ||
| MMT 95 Study For Rhabdomyosarcoma and Other Malignant Soft Tissue Tumors of Childhood[NCT00002898] | Phase 3 | 400 participants (Anticipated) | Interventional | 1995-01-31 | Completed | ||
| "A Phase II Up-Front Window Study of Irinotecan (CPT-11) Followed by Multimodal, Multiagent, Therapy for Selected Children and Adolescents With Newly Diagnosed Stage 4/Clinical Group IV Rhabdomyosarcoma: An IRS-V Study"[NCT00003955] | Phase 2 | 77 participants (Actual) | Interventional | 1999-09-30 | Completed | ||
| A Pilot Study Investigating Neoadjuvant Temozolomide-based Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas[NCT00881595] | Phase 2 | 0 participants (Actual) | Interventional | 2009-02-28 | Withdrawn (stopped due to No patients accrued since study opened) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption. AUCss is expressed in milligrams times days per milliliter (mg*day/mL). (NCT00643565)
Timeframe: Pre- and within 3 hours post-dose on Days 1, 8, and 15 of Cycle 1, Day 1 of Cycle 2-4 of induction phase
| Intervention | mg*day/mL (Mean) |
|---|---|
| Bevacizumab + Chemotherapy | 1010 |
CL is a quantitative measure of the rate at which a drug substance is removed from the body. CL is expressed in milliliters per day (mL/day). (NCT00643565)
Timeframe: Pre- and within 3 hours post-dose on Days 1, 8, and 15 of Cycle 1, Day 1 of Cycle 2-4 of induction phase (1 cycle = 3 weeks)
| Intervention | mL/day (Mean) |
|---|---|
| Bevacizumab + Chemotherapy | 167 |
Duration of Response was defined as time between first objective response and the occurrence of an EFS event (described in Outcome Measure 1). Objective response was defined in Outcome Measure 3. Median duration of response was estimated using Kaplan-Meier estimates and 95% CI for median was computed using the method of Brookmeyer and Crowley. (NCT00643565)
Timeframe: Screening up to approximately 6.75 years
| Intervention | months (Median) |
|---|---|
| Chemotherapy | NA |
| Bevacizumab + Chemotherapy | 17.48 |
EFS was defined as the time between randomization and occurrence of EFS event. EFS events are described in Outcome Measure 1. Median EFS was estimated using Kaplan-Meier estimates and 95% confidence intervals (CI) for median was computed using the method of Brookmeyer and Crowley. (NCT00643565)
Timeframe: Screening up to approximately 6.75 years (assessed at screening, Cycles 4, 7 of induction phase, Cycles 1, 4, 7, 10 of maintenance, then every 3 months for 1.5 years and thereafter every 6 months for 2.5 years)
| Intervention | months (Median) |
|---|---|
| Chemotherapy | 14.85 |
| Bevacizumab + Chemotherapy | 20.63 |
Half-life is the time measured for the plasma concentration to decrease by one half. (NCT00643565)
Timeframe: Pre- and within 3 hours post-dose on Days 1, 8, and 15 of Cycle 1, Day 1 of Cycle 2-4 of induction phase (1 cycle = 3 weeks)
| Intervention | days (Mean) |
|---|---|
| Bevacizumab + Chemotherapy | 20.8 |
Overall survival was defined as the time between randomization and death due to any cause. Participants without an event were censored at the last time they were known to be alive. Median overall survival was estimated using Kaplan-Meier estimates and 95% CI for median was computed using the method of Brookmeyer and Crowley. (NCT00643565)
Timeframe: Screening up to approximately 10.75 years (assessed at screening, Cycles 4, 7 of induction phase, Cycles 1, 4, 7, 10 of maintenance, then every 3 months for 1.5 years and thereafter every 6 months for 2.5 years)
| Intervention | months (Median) |
|---|---|
| Chemotherapy | 24.02 |
| Bevacizumab + Chemotherapy | 32.79 |
(NCT00643565)
Timeframe: Screening up to approximately 10.75 years (assessed at screening, Cycles 4, 7 of induction phase, Cycles 1, 4, 7, 10 of maintenance, then every 3 months for 1.5 years and thereafter every 6 months for 2.5 years.
| Intervention | percentage of participants (Number) |
|---|---|
| Chemotherapy | 50 |
| Bevacizumab + Chemotherapy | 51.4 |
EFS events was described in Outcome Measure 1 and Outcome Measure 3. (NCT00643565)
Timeframe: Screening up to approximately 6.75 years
| Intervention | percentage of participants (Number) |
|---|---|
| Chemotherapy | 40.7 |
| Bevacizumab + Chemotherapy | 76.5 |
EFS events included tumor progression (IRC assessed), no evidence of response after 3 cycles of induction (derived from IRC assessment), second primary cancer, or death due to any cause. Data for participants who had not experienced an event by the time of clinical cut-off were censored at the date of the last disease assessment prior to the clinical cut-off date. Data for participants who did not have any post-baseline disease assessments were censored at the time of randomization. Tumor progression was defined using Response Evaluation Criteria in Solid Tumors version 1.0 (RECIST v1.0) as at least a 20% increase in the disease measurement, taking as reference the smallest disease measurement recorded since the start of treatment, or the appearance of one or more new lesions, or evidence of clinical progression and unequivocal progression of existing non-target lesions. (NCT00643565)
Timeframe: Screening up to approximately 6.75 years (assessed at screening, Cycles 4, 7 of induction phase, Cycles 1, 4, 7, 10 of maintenance, then every 3 months for 1.5 years and thereafter every 6 months for 2.5 years)
| Intervention | percentage of participants (Number) |
|---|---|
| Chemotherapy | 52.5 |
| Bevacizumab + Chemotherapy | 68.9 |
Objective response prior to first local therapy (surgery and/or radiotherapy) was defined as complete response (CR) or partial response (PR) determined on two consecutive occasions >/=4 weeks apart. Tumor response was assessed as per IRC using RECIST v1.0. CR was defined as disappearance of all target and non-target lesions. If immunocytology was available, no disease was to be detected by that methodology. PR was defined as at least a 30% decrease in the disease measurement, taking as reference the disease measurement done to confirm measurable disease at study entry. (NCT00643565)
Timeframe: Screening up to approximately 6.75 years
| Intervention | percentage of participants (Number) |
|---|---|
| Chemotherapy | 36.0 |
| Bevacizumab + Chemotherapy | 54.0 |
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state. (NCT00643565)
Timeframe: Pre- and within 3 hours post-dose on Days 1, 8, and 15 of Cycle 1, Day 1 of Cycle 2-4 of induction phase (1 cycle = 3 weeks)
| Intervention | mL (Mean) |
|---|---|
| Bevacizumab + Chemotherapy | 2070 |
15 reviews available for ifosfamide and Rhabdomyosarcoma
| Article | Year |
|---|---|
Perianal rhabdomyosarcoma in an adult: A case report and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Humans; Ifosfami | 2023 |
Successful treatment of synchronous chemoresistant pulmonary metastasis from pleomorphic rhabdomyosarcoma with stereotaxic body radiation therapy: A case report and a review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Resistance, Neoplasm; Female; Huma | 2021 |
Fifty years of rhabdomyosarcoma studies on both sides of the pond and lessons learned.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Dactinomycin; Europe; Human | 2018 |
Chemotherapy-induced differentiation to cure botryoid rhabdomyosarcoma: a case report and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cell Differentiation; Dactinomycin; Desmin; F | 2017 |
[Vincristine-induced unilateral ptosis: case report and review of the literature].
Topics: Antineoplastic Combined Chemotherapy Protocols; Blepharoptosis; Child, Preschool; Dactinomycin; Fema | 2013 |
Ifosfamide in pediatric solid tumors.
Topics: Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Cyclophosphamide; Germinoma; Humans; Ifosf | 2003 |
[Pulmonary rhabdomyosarcoma generated during treatment of testicular tumor].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Embryonal; Cisplatin; Combined Mod | 2003 |
[Soft tissue sarcoma: postoperative chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therapy; Cyclophos | 2004 |
Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; C | 2006 |
Ifosfamide nephrotoxicity in children: histopathological features in two cases.
Topics: Adult; Antineoplastic Agents, Alkylating; Biopsy; Child; Child, Preschool; Female; Humans; Ifosfamid | 1996 |
Problems and controversies in the management of childhood sarcomas.
Topics: Amputation, Surgical; Antineoplastic Agents; Child; Child, Preschool; Doxorubicin; Humans; Ifosfamid | 1996 |
Cystosarcoma phyllodes of the prostate with rhabdomyoblastic differentiation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxorubicin; Fatal | 2001 |
Concurrent ifosfamide-based chemotherapy and irradiation. Analysis of treatment-related toxicity in 43 patients with sarcoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Child, Preschool; Combined Mo | 2001 |
Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplatin; Clin | 2001 |
Chemotherapy of advanced sarcomas of bone and soft tissue.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clinical Trials as Topic; Dacarbazin | 1992 |
29 trials available for ifosfamide and Rhabdomyosarcoma
| Article | Year |
|---|---|
Long-term results from the multicentric European randomized phase 3 trial CWS/RMS-96 for localized high-risk soft tissue sarcoma in children, adolescents, and young adults.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Dactinomycin; Doxorubicin; Humans | 2022 |
Metastatic Rhabdomyosarcoma: Results of the European
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Dactinomycin; Disease-Free | 2022 |
Metastatic Rhabdomyosarcoma: Results of the European
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Dactinomycin; Disease-Free | 2022 |
Metastatic Rhabdomyosarcoma: Results of the European
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Dactinomycin; Disease-Free | 2022 |
Metastatic Rhabdomyosarcoma: Results of the European
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Dactinomycin; Disease-Free | 2022 |
An unresolved issue in rhabdomyosarcoma treatment: The duration of chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Dactinomy | 2020 |
Relapse after localized rhabdomyosarcoma: Evaluation of the efficacy of second-line chemotherapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamid | 2015 |
Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; | 2016 |
Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dose-Response Relationship | 2009 |
Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined | 2009 |
Tandem high-dose chemotherapy followed by autologous transplantation in patients with locally advanced or metastatic sarcoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Combined Modality | 2009 |
Results of RS-99 protocol for childhood solid tumors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; | 2010 |
Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatr
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Dactinomycin; | 2012 |
Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Presch | 2005 |
Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology--SIOP Malignant Mesenchymal Tumor 89.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Da | 2005 |
Soft tissue sarcoma or malignant mesenchymal tumors in the first year of life: experience of the International Society of Pediatric Oncology (SIOP) Malignant Mesenchymal Tumor Committee.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphami | 2005 |
Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk sarcomas: the St. Jude Children's Research Hospital experience.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Combined M | 2006 |
Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplatin; Cycl | 2006 |
Comparison of results of a pilot study of alternating vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide with IRS-IV in intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamid | 2008 |
[Preliminary evaluation of the effectiveness of holoxan in the treatment of malignant soft tissue and bone neoplasms].
Topics: Adolescent; Adult; Antineoplastic Agents; Bone Neoplasms; Child; Child, Preschool; Clinical Trials a | 1981 |
Primary chemotherapy in rhabdomyosarcomas and other malignant mesenchymal tumors of the orbit: results of the International Society of Pediatric Oncology MMT 84 Study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dactinomycin; H | 1994 |
Cyclophosphamide dose escalation in combination with vincristine and actinomycin-D (VAC) in gross residual sarcoma. A pilot study without hematopoietic growth factor support evaluating toxicity and response.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cyclophosphamide; Dact | 1995 |
Renal toxicity of ifosfamide in pilot regimens of the intergroup rhabdomyosarcoma study for patients with gross residual tumor.
Topics: Acute Kidney Injury; Adolescent; Adult; Chemotherapy, Adjuvant; Child; Child, Preschool; Creatinine; | 1994 |
A phase II trial of ifosfamide in previously untreated children and adolescents with unresectable rhabdomyosarcoma.
Topics: Adolescent; Adult; Child; Child, Preschool; Female; Humans; Ifosfamide; Infant; Kidney; Male; Rhabdo | 1993 |
A Southwest Oncology Group and Cancer and Leukemia Group B phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in adults with advanced osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; F | 1998 |
Treatment of non-metastatic rhabdomyosarcomas in childhood and adolescence. Results of the second study of the International Society of Paediatric Oncology: MMT84.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dactinomycin; F | 1998 |
High-dose melphalan with autologous stem-cell rescue in metastatic rhabdomyosarcoma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone | 1999 |
Efficacy of ifosfamide and doxorubicin given as a phase II "window" in children with newly diagnosed metastatic rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Doxorubi | 2001 |
Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bronchiolit | 2001 |
High-dose chemotherapy in poor-prognosis adult small round-cell tumors: clinical and molecular results from a prospective study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cyclophos | 2002 |
Treatment of rhabdomyosarcoma and other malignant mesenchymal tumours of childhood with ifosfamide + vincristine + dactinomycin (IVA) as front-line therapy (a SIOP study).
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Clinical Trials as Topic; Dactinomycin; Human | 1989 |
Comparison of the rates of response to ifosfamide and cyclophosphamide in primary unresectable rhabdomyosarcomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Dactinom | 1989 |
71 other studies available for ifosfamide and Rhabdomyosarcoma
| Article | Year |
|---|---|
A report on second neo-plasms in seven children with solid tumors.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisp | 2022 |
Patients with completely resected nongenitourinary low-risk embryonal rhabdomyosarcoma are candidates for reduced duration low-intensity chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Female; Humans; Ifosfamide; | 2022 |
An uncommon perineal embryonal rhabdomyosarcoma in adult: A case report.
Topics: Adult; Child; Humans; Ifosfamide; Irinotecan; Male; Perineum; Rhabdomyosarcoma; Rhabdomyosarcoma, Em | 2022 |
Successful treatment of stage 4 rhabdomyosarcoma in a female with Williams-Beuren syndrome.
Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; | 2020 |
VIVA (vinorelbine, ifosfamide, vincristine, actinomycin-D): A new regimen in the armamentarium of systemic therapy for high-risk rhabdomyosarcoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dactinomycin; F | 2020 |
Para-neoplastic optic neuritis presenting in a child with fusion positive localised para-testicular alveolar rhabdomyosarcoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Blindness; Cyclophosphamide; Doxorubicin | 2021 |
Management of Low and Intermediate Risk Adult Rhabdomyosarcoma: A Pooled Survival Analysis of 553 Patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anthracyclines; Cyclophosphamide; Disease Progression; F | 2018 |
Rhabdomyosarcoma in adults: analysis of treatment modalities in a prospective single-center series.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacti | 2019 |
Diagnosis and treatment of lymph node metastases in pediatric rhabdomyosarcoma in the Netherlands: a retrospective analysis.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brachytherapy; Child; Child, Pre | 2014 |
Orbital rhabdomyosarcoma in children: a favorable primary suitable for a less-invasive treatment strategy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Child; Child, Prescho | 2014 |
Primary diffuse pleural rhabdomyosarcoma in an adult patient.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Fatal Outcome; Humans; Ifosf | 2016 |
Adult Pleomorphic Rhabdomyosarcoma: A Multicentre Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Etoposi | 2015 |
Ifosfamide and etoposide chemotherapy may interact with warfarin, enhancing the warfarin induced anticoagulant response.
Topics: Adolescent; Anticoagulants; Cytochrome P-450 CYP2C9 Inhibitors; Drug Interactions; Etoposide; Humans | 2016 |
Ifosfamide and Etoposide Chemotherapy in the Treatment of Recurrent/Refractory Rhabdomyosarcoma in Adults.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Ifosfamide; | 2016 |
[Incidence and risk factors for ifosfamide-related encephalopathy in sarcoma patients].
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Diseases; Ch | 2017 |
Secondary leukemia in a child conceived using in vitro fertilization.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cerebellar Neoplasms; Chemotherapy, Adjuvant; Child, | 2008 |
Treatment of adult rhabdomyosarcoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxorubicin; | 2010 |
Long-term evaluation of Ifosfamide-related nephrotoxicity in children.
Topics: Antineoplastic Agents, Alkylating; Child; Follow-Up Studies; Humans; Ifosfamide; Kidney; Kidney Dise | 2009 |
Successful treatment of ifosfamide neurotoxicity with dexmedetomidine.
Topics: Adrenergic alpha-2 Receptor Agonists; Antidotes; Antineoplastic Agents, Alkylating; Child, Preschool | 2010 |
Infratentorial brain metastases of pediatric non-epithelial malignant tumors: three case reports.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin | 2011 |
Quantification of dimethyl-ifosfamide and its N-deschloropropylated metabolites in mouse plasma by liquid chromatography-tandem mass spectrometry.
Topics: Animals; Chromatography, Liquid; Drug Stability; Female; Humans; Ifosfamide; Least-Squares Analysis; | 2011 |
The effect of N-acetylcysteine on the antitumor activity of ifosfamide.
Topics: Acetylcysteine; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; Drug Interaction | 2011 |
[Mobilization and collection of autologous peripheral blood stem cells by CIE or IEV protocol in children with malignant solid tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Epirubicin; Etoposide; Fema | 2011 |
Patterns of chemotherapy-induced toxicities in younger children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee.
Topics: Adolescent; Age Factors; Anemia; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Presc | 2012 |
Clinical results of high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation in children with advanced stage rhabdomyosarcoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Di | 2012 |
Pleomorphic rhabdomyosarcoma in a patient with hereditary nonpolyposis colorectal cancer.
Topics: Adaptor Proteins, Signal Transducing; Adenosine Triphosphatases; Anthracyclines; Antineoplastic Comb | 2013 |
Spindle cell rhabdomyosarcoma of the prostate.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dactinomycin; Doxorubicin; Humans; Ifosfamide; Magne | 2013 |
[Pediatric rhabdomyosarcoma of the infratemporal fossa].
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Co | 2002 |
Regression of refractory rhabdomyosarcoma after allogeneic stem-cell transplantation.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cispl | 2003 |
Treatment of children with nonmetastatic paratesticular rhabdomyosarcoma: results of the Malignant Mesenchymal Tumors studies (MMT 84 and MMT 89) of the International Society of Pediatric Oncology.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modali | 2003 |
Doxorubicin potentiates TRAIL cytotoxicity and apoptosis and can overcome TRAIL-resistance in rhabdomyosarcoma cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Survival; Do | 2004 |
[A case of advanced rhabdomyosarcoma of the spermatic cord who occurred epilepsy-like symptoms, but was completely responded to chemotherapy].
Topics: Adult; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diazepam; Epileps | 2004 |
A case of primary botryoid conjunctival rhabdomyosarcoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Combined Modality The | 2006 |
Detection of chemotherapy-induced enterocyte toxicity with circulating intestinal fatty acid binding protein.
Topics: Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Biomarkers; Child | 2006 |
[Effect of modified MAID regimen for patients with advanced soft tissue sarcoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; F | 2006 |
Stage IV primitive-appearing sinus and orbital rhabdomyosarcoma presenting in a 68-year-old female previously treated for breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; D | 2008 |
Ifosfamide-induced renal tubular defect.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dactinomycin; Doxorubicin; Humans; | 1994 |
B19 parvovirus infection in children with malignant solid tumors receiving chemotherapy.
Topics: Acute Disease; Adolescent; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chil | 1994 |
Ifosfamide nephrotoxicity in paediatric cancer patients.
Topics: Adolescent; Child; Child, Preschool; Female; Glomerular Filtration Rate; Humans; Ifosfamide; Infant; | 1994 |
Metabolism of ifosfamide during a 3 day infusion.
Topics: Adenocarcinoma; Chromatography, Thin Layer; Female; Humans; Ifosfamide; Male; Neuroectodermal Tumors | 1994 |
Osteosarcoma with deeply eosinophilic rhabdomyoblast cells in a lung metastatic focus. A case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Femoral Neoplasms; | 1993 |
Adult prostatic rhabdomyosarcoma.
Topics: Adult; Combined Modality Therapy; Humans; Ifosfamide; Male; Prostatectomy; Prostatic Neoplasms; Rhab | 1993 |
Ifosfamide in the treatment of pediatric malignancies.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 1996 |
Ifosfamide and paediatrics: should this marriage be saved?
Topics: Antineoplastic Agents, Alkylating; Child; Humans; Ifosfamide; Kidney; Neoplasms; Rhabdomyosarcoma | 1996 |
Late reversibility of chronic ifosfamide-associated nephrotoxicity in a child.
Topics: Antineoplastic Agents, Alkylating; Child, Preschool; Chronic Disease; Fanconi Syndrome; Glomerular F | 1997 |
Successful treatment of orbital rhabdomyosarcoma in two infants using chemotherapy alone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dactinomycin; Doxorubicin; | 1997 |
Treatment of childhood post-irradiation sarcoma of bone in cancer survivors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; | 1997 |
Treatment of children with relapsed soft tissue sarcoma: report of the German CESS/CWS REZ 91 trial.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 1998 |
Rhabdomyosarcoma of extrahepatic biliary tree: initial treatment with chemotherapy and conservative surgery.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Child, Preschool; Dactinomy | 1998 |
End-stage renal interstitial fibrosis in an adult ten years after ifosfamide therapy.
Topics: Adult; Antineoplastic Agents, Alkylating; Fibrosis; Humans; Ifosfamide; Kidney; Kidney Failure, Chro | 1998 |
Cyclophosphamide and ifosfamide metabolites in the cerebrospinal fluid of children.
Topics: Adolescent; Antineoplastic Agents; Biotransformation; Brain Neoplasms; Child; Child, Preschool; Cycl | 1997 |
Treatment of intermediate risk rhabdomyosarcoma and undifferentiated sarcoma with alternating cycles of vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclopho | 1998 |
Granulocyte colony stimulating factor permits dose intensification by interval compression in the treatment of Ewing's sarcomas and soft tissue sarcomas in children.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2000 |
Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children's Cancer Study Group.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Child, Preschool; Cross | 2000 |
Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Female; Humans; Ifosfamide; | 2000 |
Rhabdomyosarcoma of the corpus of the uterus: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Dactinomycin; Female; Humans; Hysterectomy; I | 2000 |
Intensity modulation techniques for improvement of normal tissue tolerance.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Doxorubicin; Head and Neck Neoplasms; Humans; | 2002 |
[Cytostatic therapy of tumors under conditions of partial synchronisation with particular reference to malignant tumors of the testicle (author's transl)].
Topics: Adult; Antineoplastic Agents; Bleomycin; Cell Transformation, Neoplastic; Child; Child, Preschool; D | 1975 |
[Parameningeal cervical rhabdomyosarcoma in the neonatal period].
Topics: Antineoplastic Combined Chemotherapy Protocols; Dactinomycin; Female; Head and Neck Neoplasms; Human | 1992 |
Rhabdomyosarcoma of the head and neck in children.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modality Therapy; | 1992 |
Primary rhabdomyosarcoma of the diaphragm. Report of a case presenting with hemothorax.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Dactinomycin; Diaphragm; Doxorubicin; Hemotho | 1992 |
Reversible hypophosphatemic rickets following ifosfamide treatment.
Topics: Abdominal Neoplasms; Child; Fanconi Syndrome; Humans; Ifosfamide; Male; Neoplasm Recurrence, Local; | 1992 |
[Effects of mesna (2-mercaptoethane sodium sulfonate) in children with malignant disease receiving oxazaphosphorine chemotherapy].
Topics: Bone Neoplasms; Child; Cyclophosphamide; Cystitis; Female; Hematuria; Humans; Ifosfamide; Leukemia; | 1990 |
Efficacy, toxicity, pharmacokinetics, and in vitro metabolism of the enantiomers of ifosfamide in mice.
Topics: Animals; Female; Humans; Ifosfamide; In Vitro Techniques; Mice; Mice, Inbred CBA; Microsomes, Liver; | 1990 |
[Effect of cytostatic treatment on microsurgery vascular anastomoses].
Topics: Anastomosis, Surgical; Animals; Endothelium, Vascular; Female; Head and Neck Neoplasms; Ifosfamide; | 1990 |
Hypophosphataemic rickets after ifosfamide treatment in children.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Female; Humans; Ifosfamide; Infant | 1989 |
Fatal encephalopathy with ifosfamide/mesna.
Topics: Brain Diseases; Child; Drug Therapy, Combination; Humans; Ifosfamide; Male; Mercaptoethanol; Mesna; | 1989 |
Ifosfamide-induced Fanconi syndrome.
Topics: Child, Preschool; Facial Neoplasms; Fanconi Syndrome; Female; Humans; Ifosfamide; Rhabdomyosarcoma | 1989 |
The predictive value of initial cytostatic response in primary unresectable rhabdomyosarcoma in children.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Dactinomycin; Doxorubicin; | 1989 |
Anhydramnios and cessation of fetal growth in a pregnant mother with polychemotherapy during the second trimester.
Topics: Adult; Amniotic Fluid; Antineoplastic Combined Chemotherapy Protocols; Dactinomycin; Facial Neoplasm | 1989 |
Irreversible encephalopathy with ifosfamide/mesna.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Child, Preschool; Dactinomycin; Fema | 1987 |